对注射用多发性硬化症疗法有不同看法：它们的相似之处多于不同之处。 - Suppr | 超能文献

Seeing injectable MS therapies differently: they are more similar than different.

作者信息

Fox Robert J, Arnold Douglas L

出版信息

Neurology. 2009 Jun 9;72(23):1972-3. doi: 10.1212/WNL.0b013e3181a92c82. Epub 2009 May 13.

DOI:10.1212/WNL.0b013e3181a92c82

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Seeing injectable MS therapies differently: they are more similar than different.对注射用多发性硬化症疗法有不同看法：它们的相似之处多于不同之处。

Neurology. 2009 Jun 9;72(23):1972-3. doi: 10.1212/WNL.0b013e3181a92c82. Epub 2009 May 13.

2

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.在BECOME研究中，通过每月脑部磁共振成像评估干扰素β-1b或醋酸格拉替雷治疗多发性硬化症的疗效。

Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.

3

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?利用磁共振成像定义多发性硬化症的治疗反应：多少活动量才算过多？

Arch Neurol. 2009 Jan;66(1):19-20. doi: 10.1001/archneurol.2008.529.

4

Seeing injectable ms therapies differently: they are more similar than different.以不同视角看待注射用多发性硬化症疗法：它们的相似之处多于不同之处。

Neurology. 2010 Feb 23;74(8):702. doi: 10.1212/WNL.0b013e3181c77773.

5

The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.干扰素β-1a对多发性硬化症患者质子磁共振波谱成像的影响：一项对照研究的初步结果

Int J Neurosci. 2008 Dec;118(12):1645-58. doi: 10.1080/00207450802309680.

6

High sensitivity measurement of CRP and disease progression in multiple sclerosis.多发性硬化症中CRP的高灵敏度测量与疾病进展

Neurology. 2005 Jul 12;65(1):153-5. doi: 10.1212/01.wnl.0000167129.90918.f5.

7

The use of MRI as an outcome measure in clinical trials.磁共振成像（MRI）在临床试验中作为一种疗效指标的应用。

Adv Neurol. 2006;98:203-26.

8

Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.成长：免疫调节疗法在儿童多发性硬化症中的应用。

Neurology. 2005 Mar 8;64(5):778-9. doi: 10.1212/01.WNL.0000153532.80277.21.

9

Early treatment of multiple sclerosis to prevent neurologic damage.多发性硬化症的早期治疗以预防神经损伤。

Neurology. 2008 Dec 9;71(24 Suppl 3):S3-7. doi: 10.1212/WNL.0b013e31818f3d6f.

10

Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.复发缓解型多发性硬化症的疾病修正治疗：疗效至关重要。

Int J Clin Pract Suppl. 2002 Sep(131):3-7.

引用本文的文献

1

Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.多发性硬化一线注射用疾病修正疗法的变化：药物不依从、换药、停药及中断治疗的预测因素

Neurol Sci. 2017 Apr;38(4):589-594. doi: 10.1007/s10072-016-2806-4. Epub 2017 Jan 11.

2

Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.注射用疾病修正疗法的治疗中断与疾病进展：来自北美多发性硬化症研究委员会数据库的研究结果

Int J MS Care. 2013 Winter;15(4):194-201. doi: 10.7224/1537-2073.2012-034.